이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

2018년 8월 7일 업데이트: GlaxoSmithKline

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease

The study is designed to investigate the effects of rilapladib on biomarkers related to the Alzheimer's disease, and cognitive function.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

The study is in subjects with Alzheimer's disease and evidence of cerebrovascular disease (CVD) who are currently treated with an acetylcholinesterase inhibitor (AChEI) and/or memantine. The study is a randomized, double-blind, placebo controlled, parallel group, repeat dose design, in which subjects (up to 60 randomized subjects per arm) will receive oral placebo or rilapladib (250 mg), once daily for 24 weeks in addition to their stable background AD therapy consisting of an acetylcholinesterase inhibitor (AChEI) and/or memantine. Subjects will take 250mg of rilapladib or placebo once daily for a period of 24 weeks. The total duration of participation for each subject will be approximately 30 weeks comprising approximately 4 weeks screening, 24 weeks treatment and 2 weeks follow-up. From the time of randomization and throughout the treatment period subjects will attend visits after 1 week, 4 weeks and thereafter every 4 weeks until Week 24. A follow-up visit will occur approximately 2 weeks after the final dose of study medication. Cognitive assessments will be performed at the screening visit, at the randomization (baseline) visit and at weeks 12 and 24 of the treatment period. Cerebrospinal fluid (CSF) samples will be taken via lumbar puncture at baseline and Week 24 for biomarker analyses related to Alzheimer's disease. Blood samples will be collected throughout the study for pharmacokinetics and a range of biomarker analyses. A range of safety and tolerability assessments will also be performed (including vital signs, laboratory tests, eye examinations and ECGs).

연구 유형

중재적

등록 (실제)

124

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 노르웨이
      • Lørenskog, 노르웨이, 1478
        • GSK Investigational Site
  • 독일
    • Baden-Wuerttemberg
      • Ellwangen, Baden-Wuerttemberg, 독일, 73479
        • GSK Investigational Site
      • Tuebingen, Baden-Wuerttemberg, 독일, 72076
        • GSK Investigational Site
      • Ulm, Baden-Wuerttemberg, 독일, 89081
        • GSK Investigational Site
    • Bayern
      • Alzenau, Bayern, 독일, 63755
        • GSK Investigational Site
    • Hessen
      • Bad Homburg, Hessen, 독일, 61348
        • GSK Investigational Site
    • Niedersachsen
      • Achim, Niedersachsen, 독일, 28832
        • GSK Investigational Site
      • Hannover, Niedersachsen, 독일, 30559
        • GSK Investigational Site
    • Nordrhein-Westfalen
      • Bochum, Nordrhein-Westfalen, 독일, 44787
        • GSK Investigational Site
      • Bochum, Nordrhein-Westfalen, 독일, 44791
        • GSK Investigational Site
      • Bochum, Nordrhein-Westfalen, 독일, 44892
        • GSK Investigational Site
      • Koeln, Nordrhein-Westfalen, 독일, 50935
        • GSK Investigational Site
    • Schleswig-Holstein
      • Oldenburg, Schleswig-Holstein, 독일, 26122
        • GSK Investigational Site
  • 불가리아
      • Sofia, 불가리아, 1431
        • GSK Investigational Site
      • Sofia, 불가리아, 1113
        • GSK Investigational Site
  • 스웨덴
      • Stockholm, 스웨덴, SE-141 86
        • GSK Investigational Site
  • 스페인
      • Baracaldo/Vizcaya, 스페인, 48903
        • GSK Investigational Site
      • Barcelona, 스페인, 08014
        • GSK Investigational Site
      • Castellón de La Plana, 스페인, 12004
        • GSK Investigational Site
      • Getafe/Madrid, 스페인, 28905
        • GSK Investigational Site
      • L'Hospitalet de Llobregat, 스페인, 08907
        • GSK Investigational Site
      • Madrid, 스페인, 28006
        • GSK Investigational Site
  • 이탈리아
    • Lazio
      • Roma, Lazio, 이탈리아, 00185
        • GSK Investigational Site
    • Liguria
      • Genova, Liguria, 이탈리아, 16132
        • GSK Investigational Site
    • Lombardia
      • Brescia, Lombardia, 이탈리아, 25125
        • GSK Investigational Site
      • Milano, Lombardia, 이탈리아, 20122
        • GSK Investigational Site
    • Veneto
      • Verona, Veneto, 이탈리아, 37134
        • GSK Investigational Site
  • 캐나다
    • Ontario
      • Toronto, Ontario, 캐나다, M3B 2S7
        • GSK Investigational Site
    • Quebec
      • Gatineau, Quebec, 캐나다, J9A 1K7
        • GSK Investigational Site
      • Sherbrooke, Quebec, 캐나다, J1H 1Z1
        • GSK Investigational Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

50년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. A clinical diagnosis of possible Alzheimer's disease in accordance with the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with radiological (Magnetic Resonance Imaging [MRI] or Computed Tomography [CT]) evidence of significant cerebrovascular disease (CVD), assessed within the last 12 months
  2. Male or female between 50 and 80 years of age inclusive, at the time of signing the informed consent.
  3. Subject has a documented history of at least 6 months of ongoing Alzheimer's disease therapy (AChEIs and/or memantine) with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
  4. Mini-Mental Status Examination (MMSE) score between 20 and 26 at Screening.
  5. Clinical Dementia Rating Scale (CDR) score of 0.5 or 1.0 at Screening.
  6. A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea; or of child-bearing potential and agrees to use acceptable contraception methods
  7. Subject has provided full written informed consent prior to the performance of any protocol-specified procedure; or if the subject is unable to provide informed consent due to cognitive status, the subject will provide assent and full written informed consent will be provided by a legally acceptable representative
  8. The subject has a dedicated caregiver who is willing to supervise participation in the study
  9. In the opinion of the investigator, the subject has the ability to comply with study procedures (cognitive and other testing) and is fluent in the language used for the administration of the cognitive tests.

Exclusion Criteria:

  1. History and/or evidence of any other CNS disorder that could be interpreted as a cause of dementia: e.g. structural or developmental abnormality, epilepsy, infectious, degenerative or inflammatory/demyelinating CNS conditions such as, Parkinson's disease and frontotemporal dementia
  2. History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study; major depressive disorder (according to DSM-IV) in the past year; current active depression requiring initiation of treatment (or is believed to account for substantial degree of cognitive impairment)
  3. Evidence of the following disorders: current vitamin B12 deficiency, positive syphilis serology (unless neurosyphilis was ruled out) or active thyroid dysfunction (particularly suggestive of hypothyroidism), including abnormally high or low serum levels of thyroid stimulating hormone (TSH), where this is thought to be the cause of, or to contribute to the severity of the subject's dementia.
  4. History of alcohol or other substance abuse, according to the DSM-IV criteria, or recent or remote history of the same if that could be a contributing factor to dementia.
  5. History of intra cerebral haemorrhage due to any of the following causes: cerebral amyloid angiopathy, uncontrolled hypertension, cerebral arteriovenous malformation, coagulopathy, CNS vasculitis or any other condition that the investigator and/or medical monitor considers as a relevant risk factor for intracerebral haemorrhage

  6. Recent (i.e.,<6 months from Screening Visit) cardiovascular event defined as:

    1. ST-elevation MI or non-ST-elevation MI, confirmed by cardiac enzyme elevation and ECG changes
    2. coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft )
    3. stroke of any etiology
    4. resuscitated sudden death
    5. prior carotid surgery or stenting procedure
  7. Poorly controlled hypertension despite lifestyle modifications and pharmacotherapy (either systolic blood pressure >160mmHg or diastolic blood pressure >110mmHg)
  8. QTcB interval >450 msec; or QTcB > 480 msec in subjects with bundle branch block based on ECG assessment at the Screening visit.
  9. HbA1c >12.0 at Screening, or uncontrolled diabetes in the opinion of the investigator.
  10. History of glaucoma or any other findings in the baseline eye exam that, in the opinion of the investigator, would exclude the subject from participation in the study.
  11. History of adult asthma (or reactive airway disease) manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s).
  12. Previous history of anaphylaxis, severe allergic reaction or history of hypersensitivity to any of the components of the formulation.
  13. Significant abnormalities on clinical chemistry, haematology or urinalysis at Screening, including clinically significant anaemia.
  14. History of chronic viral hepatitis (including presence of B surface antigen or hepatitis C antibody), or other chronic hepatic disorders.

  15. Abnormal Screening blood tests exceeding any of the limits defined below:

    1. Alanine transaminase (ALT) or aspartate transaminase (AST) >1.5 x the upper limit of normal (ULN)
    2. Alkaline phosphatase (AP) and bilirubin >1.5X ULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
    3. Calculated creatinine clearance < 30 ml/min (per Cockcroft & Gault) at Screening
  16. Other clinically significant abnormality on physical (including neurological), laboratory or ECG examination that could be detrimental to the subject in the opinion of the Investigator or could compromise the integrity of the study.
  17. Planned major surgery within the study period.
  18. Use of systemic steroids or other immunosuppressants within the last 30 days prior to screening.
  19. Current treatment with barbiturates, MAO inhibitors, butyrophenones, phenothiazines and other "conventional" antipsychotic within 30 days or 5 half-lives prior to Screening, whichever is longer.
  20. Treatment with antidepressants, (other than MAO inhibitors), thyroid hormones, atypical antipsychotics (e.g. risperidone), benzodiazepines and other sedatives / hypnotics unless prescribed at a stable dose for at least 2 months prior to Screening. Note: Benzodiazepines or other sedatives/hypnotics (including antihistamines) with half-life less than 6 hours can be taken on a prn (as needed) basis but must not be taken within 5 half lives prior to cognitive testing.
  21. Current treatment with known potent inhibitors of CYP3A4 (e.g. ketoconazole, rifampin, modafinil).
  22. Current treatment with known potent Pgp inhibitors (itraconazole, ketoconazole, cyclosporin, loperamide, diltiazem, verapamil, spironolactone, quinidine, bepridil, quinine, carvedilol)
  23. Cognitive tasks prescribed for cognitive rehabilitation and performed under medical supervision in the 6 months prior to screening and/or during study
  24. Investigational medications or devices including symptomatic AD treatment during the 60 days prior to the Screening visit, or within 5 half-lives of use of the investigational drug prior to the Screening Visit, whichever is longer.

  25. Participation in another investigational drug (with the exception of anti-amyloid monoclonal antibodies [mAbs]) or device study where subject was treated chronically (i.e. > 1 single dose) with a study agent intended to impact AD progression during the 12 months prior to the Screening visit.

    1. Subjects who participated in an investigational drug study that involved chronic dosing with a monoclonal antibody at any time in the past are excluded from this study, unless it is known that they received placebo during the previous study.
    2. Subjects who participated in previous single-dose studies of anti-amyloid mAbs will be permitted provided the subject's dose of the mAb is at least 5 half-lives removed; the subjects did not experience any moderate adverse events classified as possibly drug-related or any serious adverse event during that study; the subject did not drop out of the previous study (i.e. completed all safety assessments)
  26. Subjects, who in the investigator's judgement, pose a significant suicide risk (e.g. history of suicidal behaviour in the last 6 months and/or any suicidal ideation of type 4 or 5 on the C-SSRS in the last 2 months).
  27. Subject or caregiver is an immediate family member or employee of the participating Investigator, any of the participating site staff or GSK staff.

  28. Any contraindication to lumbar puncture or insertion of CSF catheter, including but not limited to

    1. Thrombocytopenia or other coagulation disorders (including subjects receiving coumarin-derived anti-coagulants or low-molecular-weight heparin).
    2. The presence of cutaneous or soft tissue infection overlying or adjacent to the site of lumbar puncture.
    3. Previous spinal surgery that could complicate access to the subarachnoid space.
    4. Suspicion of increased intracranial pressure due to a cerebral mass.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 250mg rilapladib
Experimental drug
의약품: 250mg rilapladib
Experimental Drug
위약 비교기: 위약
위약 비교기
의약품: 위약
위약 대조

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24
기간: Baseline (Day 0) and Week 24
CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42 and Abeta40 are summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in CSF Abeta42/ Abeta40 Ratio at Week 24
기간: Baseline (Day 0) and Week 24
CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42/Abeta40 ratio is summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24
기간: Baseline (Day 0) and Week 24
CSF tau and P-tau were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF tau and P-tau was summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in the Computerized Test Battery for Cognition (CogState) Battery Working Memory/Executive Function (WM/EF) Composite Score at Week 24
기간: Baseline (Day 0) and Week 24
The WM/EF composite score was comprised of 5 functional tests including 1) Controlled oral word association which measured language fluency, planning and working memory, 2) Category naming: It measures semantic fluency, planning and working memory, 3) One-back: This is a measure of working memory. 4) Trail B: This is a measure of motor speed, visual scanning, and visual-motor integration. This test required attention and cognitive flexibility. 5) Go No-Go task: This test evaluate accuracy and reaction time for each response. The composite score calculated by standardizing the total score: sum of all responses obtained from these 5 functional test by using the formula (Total score of ITT population at baseline - Total score at Week 24) /standard deviation of mean total mean score at baseline. The observed composite score ranged from minimum -1.474 and maximum 1.596. Lower score means better cognitive status. Change from Baseline was calculated as post-dose visit minus Baseline value.
Baseline (Day 0) and Week 24

2차 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline (Day 0) in CSF Albumin Quotients at Week 24
기간: Baseline (Day 0) and Week 24
CSF albumin quotient was assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in albumin quotient is summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24
기간: Baseline (Day 0) and Week 24
Plasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in plasma Abeta42 and Abeta40 are summarized. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in Plasma Levels of Abeta42/Abeta40 Ratio at Week 24
기간: Baseline (Day 0) and Week 24
Plasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in plasma Abeta42/Abeta40 ratio is summarized. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Percentage Inhibition in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity at Week 24
기간: Baseline (Day 0) and Week 24
Plasma Lp-PLA2 was assessed at Baseline visit (Day 0) and Week 24 (Day 168). Percentage inhibition in plasma Lp-PLA2 activity ratio is summarized. Percentage inhibition was calculated by dividing change from Baseline in plasma LpPLA2 by Baseline LpPLA2 multiplied by -100. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in CogState Battery Overall Composite Score
기간: Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
CogState battery overall composite score comprised of 8 functional tests 1) Controlled oral word association test measured language fluency, planning and working memory. 2) Category naming test measured semantic fluency, planning and working memory. 3) One-back test measured working memory. 4) Trail B test measured motor speed, visual scanning and visual-motor integration, required attention and cognitive flexibility. 5) Go No-Go task evaluated accuracy and reaction time for each response. 6) International shopping list immediate and delayed recall tests measured episodic memory. 7) Identification task test assessed visual attention. 8) Trail A test measured psychomotor speed and attention. Composite score= total score (sum of all responses from 8 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline. Score ranged: -1.070 to 0.907. Lower score indicated the better cognitive status. Change from Baseline= post-dose visit minus Baseline value
Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
Change From Baseline (Day 0) in CogState Battery Attention Composite Score
기간: Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
CogState battery attention composite score comprised of 2 functional tests including 1) Identification task test assessed visual attention and 2) Trail A test measured psychomotor speed and attention. Composite score calculated by standardizing the total score (sum of all responses from 2 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline. The observed composite score ranged from minimum -1.756 and maximum 1.330. Higher score indicated the better attention. Baseline value was defined as the latest Day 0 value and Change from Baseline was calculated as post-dose visit minus Baseline value
Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

GlaxoSmithKline

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2011년 10월 1일

기본 완료 (실제)

2013년 2월 4일

연구 완료 (실제)

2013년 2월 18일

연구 등록 날짜

최초 제출

2011년 9월 1일

QC 기준을 충족하는 최초 제출

2011년 9월 1일

처음 게시됨 (추정)

2011년 9월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2018년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2018년 8월 7일

마지막으로 확인됨

2017년 7월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 114458

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

연구 데이터/문서

  1. 데이터 세트 사양
    정보 식별자: 114458
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  2. 개별 참가자 데이터 세트
    정보 식별자: 114458
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  3. 정보에 입각한 동의서
    정보 식별자: 114458
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  4. 통계 분석 계획
    정보 식별자: 114458
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  5. 연구 프로토콜
    정보 식별자: 114458
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  6. 주석이 달린 사례 보고서 양식
    정보 식별자: 114458
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  7. 임상 연구 보고서
    정보 식별자: 114458
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

알츠하이머병에 대한 임상 시험

위약에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Ecuador

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

구독하다